Yang Z - Search Results

1

Potential treatment approaches for malignant peritoneal mesothelioma: in vivo and in vitro experimental study of natural killer cell immunotherapy.

Wu H, Wang Y, Lin Y, Ma R, Du X, Su Y, Yang R, Yang Z, Liang X, Zhang Y, Liang X, Ji Z, Lai C, Huang Y, Li Y. Wu H, et al. Among authors: yang r, yang z. Cancer Biol Med. 2024 Nov 1;21(11):1078-94. doi: 10.20892/j.issn.2095-3941.2024.0218. Cancer Biol Med. 2024. PMID: 39485065 Free PMC article.

2

Establishment of patient-derived xenograft model of peritoneal mucinous carcinomatosis with signet ring cells and in vivo study on the efficacy and toxicity of intraperitoneal injection of 5-fluorouracil.

Lin YL, Zhang J, Yan FC, Jiang X, Ma R, Yang ZR, Xu HB, Peng Z, Chen Q, Li Y. Lin YL, et al. Among authors: yang zr. Cancer Med. 2020 Feb;9(3):1104-1114. doi: 10.1002/cam4.2766. Epub 2019 Dec 8. Cancer Med. 2020. PMID: 31814323 Free PMC article.

3

Drug sensitivity tumor cell clusters in malignant peritoneal mesothelioma.

Su YD, Ma R, Fu YB, Wu HL, Liang XL, Liu YT, Yu Y, Yang ZR, Li Y. Su YD, et al. J Surg Oncol. 2024 Aug 25. doi: 10.1002/jso.27847. Online ahead of print. J Surg Oncol. 2024. PMID: 39183488

4

Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo.

Yang ZR, Chen ZG, Du XM, Li Y. Yang ZR, et al. Front Oncol. 2020 Dec 7;10:585079. doi: 10.3389/fonc.2020.585079. eCollection 2020. Front Oncol. 2020. PMID: 33365269 Free PMC article.

5

Establishment and histopathological study of patient-derived xenograft models and primary cell lines of epithelioid malignant peritoneal mesothelioma.

Yang ZR, Chen ZG, Ji ZH, Lin YL, Zhang J, Ma R, Li Z, Jiang X, Chen Q, Du XM, Li Y. Yang ZR, et al. Exp Anim. 2021 May 13;70(2):225-235. doi: 10.1538/expanim.20-0119. Epub 2021 Jan 21. Exp Anim. 2021. PMID: 33473097 Free PMC article.

6

Key factors for successful cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat diffuse malignant peritoneal mesothelioma: results from specialized peritoneal cancer center in China.

Su YD, Yang ZR, Li XB, Yu Y, Du XM, Li Y. Su YD, et al. Int J Hyperthermia. 2022;39(1):706-712. doi: 10.1080/02656736.2022.2066728. Int J Hyperthermia. 2022. PMID: 35485308 Free article.

7

NPM2 in malignant peritoneal mesothelioma: from basic tumor biology to clinical medicine.

Wu HL, Yang ZR, Yan LJ, Su YD, Ma R, Li Y. Wu HL, et al. World J Surg Oncol. 2022 Apr 30;20(1):141. doi: 10.1186/s12957-022-02604-3. World J Surg Oncol. 2022. PMID: 35490253 Free PMC article. Review.

8

Efficacy and Adverse Events of Apatinib Salvage Treatment for Refractory Diffuse Malignant Peritoneal Mesothelioma: A Pilot Study.

Yang ZR, Su YD, Ma R, Wu HL, Li Y. Yang ZR, et al. Front Oncol. 2022 Jul 1;12:811800. doi: 10.3389/fonc.2022.811800. eCollection 2022. Front Oncol. 2022. PMID: 35847956 Free PMC article.

9

Loss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases.

Wu HL, Yang ZR, Su YD, Ma R, Du XM, Gao Y, Li Y. Wu HL, et al. World J Surg Oncol. 2022 Oct 24;20(1):350. doi: 10.1186/s12957-022-02811-y. World J Surg Oncol. 2022. PMID: 36280841 Free PMC article.

10

Establishment of a Bayesian network model to predict the survival of malignant peritoneal mesothelioma patients after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy.

Su YD, Zhao X, Ma R, Fu YB, Yang ZR, Wu HL, Yu Y, Yang R, Liang XL, Du XM, Chen Y, Li Y. Su YD, et al. Int J Hyperthermia. 2023;40(1):2223374. doi: 10.1080/02656736.2023.2223374. Int J Hyperthermia. 2023. PMID: 37348853 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49,677 results

Search Page

Filters